The News

Endotis Pharma invited to present at the 28th Annual JP Morgan Healthcare Conference in San Francisco

05/01/2010

Biocitech Park, Paris, France, January 5th, 2010 - Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small-glyco drugs for applications in thrombosis and oncology, today announced that it will present at the 28th Annual JP Morgan Healthcare Conference (to be held in San Francisco January 11th through 14th, 2010). Endotis Pharma's CEO Charles Woler will give a presentation at 8 am Pacific Time, on Monday January 11th, 2010 in room F. He commented that “Endotis Pharma is one of the few private companies that have been selected at the JP Morgan conference and I am delighted to have an opportunity to present our recent developments and corporate strategy at the worldrenowned JP Morgan Healthcare Conference”. The presentation will be made available on Endotis Pharma’s website.

About Endotis Pharma
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (heparin/heparan sulfate mimetics) for applications in thrombosis and oncology. The company has a pipeline of preclinical and clinical stage products addressing niche indications (with high unmet needs) within the thrombosis and oncology fields, allowing faster market access with limited costs and risks. The value of this platform has been demonstrated by Endotis' breakthrough thrombosis franchise of parenteral and oral drugs and a promising oncology pipeline. Endotis has 35 employees based in Paris and Lille (France).

Disclaimer: The development of new drug technologies is difficult, erratic and unpredictable. Endotis Pharma’s forecasts and future economic performance depend on research that has yet to be performed and on a number of other factors. The company's future economic performance may differ significantly from that currently forecast.

For more information:
Press contact: Alize RP
Caroline Carmagnol
+33 (0)6 64 18 99 59
caroline@alizerp.com
Juliette Vandenbroucque
+ 33 (0)1 41 22 07 32
juliette@alizerp.com
Investor contact: Endotis Pharma
Charles Woler, Chairman and CEO
charleswoler@endotis.com
Stéphane Degove, Head of Finance
stephanedegove@endotis.com
+33 (0)1 48 46 84 87